Page 1

Exhibit 99.1 Galápagos Galapagos reports H1 financial results with refocused pipeline and operational progress • First half - year 2021 financial results : 0 Group revenues and other income of € 277.2 million 0 0 Net loss of € 55.0 million Operating loss of € 97.6 million O Cash and current financial investments of € 5.0 billion on June 30 , 2021 • Advancing refocused pipeline ; encouraging clinical read - outs reported in earlier - stage inflammatory programs Commercial launch of filgotinib in Europe on track • Executing on operational restructuring and savings program Webcast presentation tomorrow , August 6 , 2021 , at 14.00 CET / 8 AM ET , www.glpg.com , +32 2 793 38 47 , code 8245817 Mechelen , Belgium ; August 5 , 2021 , 22.01 CET ; regulated information - Galapagos NV ( Euronext & NASDAQ : GLPG ) is pleased to report progress on earlier - stage programs as well as its commercial launch of filgotinib in Europe . Following the recent setbacks , the company is moving forward with its revised strategy and operational restructuring announced in May . The unaudited H1 financial and operational results are further detailed in the H1 2021 report available on the website , www.glpg.com . " Multiple assets are moving through clinical development , and we recently reported positive topline data on our TYK2 compound GLPG3667 . In a Phase 1b trial in psoriasis ( Pso ) , clinical activity was observed at 4 weeks , combined with an encouraging safety and tolerability profile . We are currently running an extended dose escalation study in healthy volunteers , and plan to progress GLPG3667 to a Phase 2b dose finding study in Pso as well as a Phase 2 study in ulcerative colitis ( UC ) in 2022 . We continue to develop our SIK portfolio of molecules , and recently reported encouraging early data from the first patient studies with SIK2 / 3 inhibitor GLPG3970 . In a Phase 1b trial in Pso ( CALOSOMA ) , clinical activity was observed at 6 weeks , and in a Phase 2a trial in UC ( SEA TURTLE ) , biologically important effects were observed on a number of objective endpoints , both of which point to the potential of SIK inhibition as a novel mode of action in inflammation . No activity was observed in the LADYBUG study in rheumatoid arthritis ( RA ) . GLPG3970 was generally safe and well tolerated . Based on these encouraging data , we work on optimizing the pharmacology of follow - up compounds from our SIK portfolio , and plan to bring an improved SIK2 / 3 molecule into the clinic in 2022 . On the commercial side , we report rapid progress in establishing our commercial operations for Jyseleca across Europe , with 11 countries launched to date . Reimbursement procedures are on track , and we are on target to achieve our commercial objectives . We remain excited about the potential of our target discovery platform , our drug development capabilities , and the strength of our teams . We want to thank our shareholders for their continued support and patience as we are working hard to build our pipeline and establish Galapagos as a fully integrated European biopharma , " said Onno van de Stolpe , CEO of Galapagos . Bart Filius , President and COO , added , " Following the strategic exercise announced at Q1 , we are focused on advancing our pipeline , implementing our savings program , and diligently evaluating business development opportunities . At the same time , we have been delivering on the launch of Jyseleca , building out our organization in new European markets . In line with our review , we reiterate our 2021 operational cash burn¹ guidance of between € 580 million and € 620 million . We believe that the decisions and actions taken put us on the strongest footing for the future . We look forward to a busy second half of the year , not the least of which is the expected outcome of the regulatory review in Europe of Jyseleca in UC . "